HGNC Approved Gene Symbol:APRG1
Cytogenetic location:3p22.2 Genomic coordinates(GRCh38) :3:37,381,077-37,435,497 (from NCBI)
By database analysis to identify putative coding sequences in a region of chromosome 3 associated with carcinomas,Protopopov et al. (2003) identified several splice variants of APRG1, which they designated variants A through G. The longest protein, encoded by isoform B, contains 170 amino acids and has a calculated molecular mass of 18.5 kD. It has a putative cell attachment sequence, arg-gly-asp, a C-terminal transmembrane domain, and possible sites for phosphorylation, N-myristoylation, and amidation. Northern blot analysis revealed low abundance of APRG1 mRNA. PCR analysis detected variants B and D highly expressed in pancreas, variant A highly expressed in kidney, and variants B and C highly expressed in placenta.
Leris et al. (2005) found that the level of APRG1 mRNA was lower in malignant breast tissue than in normal tissue. Furthermore, APRG1 expression fell with increasing stage using the tumor-module-metastasis (TNM) classification, and became statistically significant when TNM stages 3 and 4 were compared to TNM stage 1.
Protopopov et al. (2003) determined that the APRG1 gene contains at least 7 exons and spans about 36.3 kb. There are 2 putative promoter/enhancer sites, the second of which is upstream of exon 2 and contains binding sites for the transcription factors LYF1 (603023), delta-EF1 (189909), TCF11 (163260), GATA (see305371), and others.
Using FISH and a deletion cell hybrid panel,Protopopov et al. (2003) mapped the APRG1 gene to chromosome 3p21.3.
Gross (2021) mapped the APRG1 gene to chromosome 3p22.2 based on an alignment of the APRG1 sequence (GenBankBC100861) with the genomic sequence (GRCh38).
Gross, M. B.Personal Communication. Baltimore, Md. 8/16/2021.
Leris, A. C. A., Roberts, T. R., Jiang, W. G., Newbold, R. F., Mokbel, K.Evidence for a tumour suppressive function of APRG1 in breast cancer. Breast Cancer Res. Treat. 93: 97-100, 2005. [PubMed:16187228,related citations] [Full Text]
Protopopov, A., Kashuba, V., Zabarovska, V. I., Muravenko, O. V., Lerman, M. I., Klein, G., Zabarovsky, E. R.An integrated physical and gene map of the 3.5-Mb chromosome 3p21.3 (AP20) region implicated in major human epithelial malignancies. Cancer Res. 63: 404-412, 2003. [PubMed:12543795,related citations]
Alternative titles; symbols
HGNC Approved Gene Symbol: APRG1
Cytogenetic location: 3p22.2 Genomic coordinates(GRCh38) : 3:37,381,077-37,435,497(from NCBI)
By database analysis to identify putative coding sequences in a region of chromosome 3 associated with carcinomas, Protopopov et al. (2003) identified several splice variants of APRG1, which they designated variants A through G. The longest protein, encoded by isoform B, contains 170 amino acids and has a calculated molecular mass of 18.5 kD. It has a putative cell attachment sequence, arg-gly-asp, a C-terminal transmembrane domain, and possible sites for phosphorylation, N-myristoylation, and amidation. Northern blot analysis revealed low abundance of APRG1 mRNA. PCR analysis detected variants B and D highly expressed in pancreas, variant A highly expressed in kidney, and variants B and C highly expressed in placenta.
Leris et al. (2005) found that the level of APRG1 mRNA was lower in malignant breast tissue than in normal tissue. Furthermore, APRG1 expression fell with increasing stage using the tumor-module-metastasis (TNM) classification, and became statistically significant when TNM stages 3 and 4 were compared to TNM stage 1.
Protopopov et al. (2003) determined that the APRG1 gene contains at least 7 exons and spans about 36.3 kb. There are 2 putative promoter/enhancer sites, the second of which is upstream of exon 2 and contains binding sites for the transcription factors LYF1 (603023), delta-EF1 (189909), TCF11 (163260), GATA (see 305371), and others.
Using FISH and a deletion cell hybrid panel, Protopopov et al. (2003) mapped the APRG1 gene to chromosome 3p21.3.
Gross (2021) mapped the APRG1 gene to chromosome 3p22.2 based on an alignment of the APRG1 sequence (GenBank BC100861) with the genomic sequence (GRCh38).
Gross, M. B.Personal Communication. Baltimore, Md. 8/16/2021.
Leris, A. C. A., Roberts, T. R., Jiang, W. G., Newbold, R. F., Mokbel, K.Evidence for a tumour suppressive function of APRG1 in breast cancer. Breast Cancer Res. Treat. 93: 97-100, 2005. [PubMed: 16187228] [Full Text: https://doi.org/10.1007/s10549-005-4169-z]
Protopopov, A., Kashuba, V., Zabarovska, V. I., Muravenko, O. V., Lerman, M. I., Klein, G., Zabarovsky, E. R.An integrated physical and gene map of the 3.5-Mb chromosome 3p21.3 (AP20) region implicated in major human epithelial malignancies. Cancer Res. 63: 404-412, 2003. [PubMed: 12543795]
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM